Lexston Life Sciences Corp. (TSE:LEXT)
:LEXT
LEXT Stock Chart & Stats
C$0.10
<C$0.01(11.11%)
At close: 4:00 PM EST
C$0.10
<C$0.01(11.11%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.34
Previous CloseN/A
Volume1.00M
Average Volume (3M)40.70K
Market Cap
C$1.76M
Enterprise ValueC$497.92K
Total Cash (Recent Filing)C$17.46K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Sep 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding25,093,304
10 Day Avg. Volume77,591
30 Day Avg. Volume40,703
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)13.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet Strength (No Debt)Absence of reported debt materially lowers fixed financial obligations and interest burden for a pre-revenue firm. This structural strength preserves financial flexibility, reduces bankruptcy risk, and gives management time to pursue exploration and milestone delivery without servicing debt.
Completed Financing For OperationsA completed $500k private placement that funded Phase 1 exploration shows management can both raise capital and immediately deploy it toward operational milestones. That funding extends runway, supports technical progress, and makes near-term advancement toward resource or value-creating events more feasible.
Demonstrated Access To CapitalRecent corporate updates and successful financing demonstrate the company's ability to attract investor capital despite being pre-revenue. For an explorer, proven access to external funding is a durable enabler to execute projects and bridge the long lead time to revenue or monetizable assets.
Bears Say
Pre-revenue With Persistent LossesThe company reports no meaningful revenue and sustained net losses (FY2025 net loss ~-1.6M; TTM ~-1.45M). Structural absence of operating revenues limits operating leverage and means the business cannot self-sustain; ongoing losses erode shareholder value over months without clear revenue trajectory.
Consistently Negative Cash FlowTTM operating cash flow and free cash flow are roughly -0.95M and have worsened year-over-year. Persistent negative cash generation prevents self-funding of exploration and operations, forcing recurring external financing and limiting strategic flexibility to invest or withstand setbacks.
Eroding/Volatile Equity And Negative ROEBalance-sheet commentary notes volatile, declining equity and deeply negative returns on equity driven by ongoing losses. Structural erosion of shareholders' equity reduces borrowing capacity, increases funding risk, and undermines long-term capital stability if losses persist.
Lexston Life Sciences Corp. News
LEXT FAQ
What was Lexston Life Sciences Corp.’s price range in the past 12 months?
Lexston Life Sciences Corp. lowest stock price was C$0.06 and its highest was C$0.34 in the past 12 months.
What is Lexston Life Sciences Corp.’s market cap?
Lexston Life Sciences Corp.’s market cap is C$1.76M.
When is Lexston Life Sciences Corp.’s upcoming earnings report date?
Lexston Life Sciences Corp.’s upcoming earnings report date is Sep 21, 2026 which is in 170 days.
How were Lexston Life Sciences Corp.’s earnings last quarter?
Lexston Life Sciences Corp. released its earnings results on Apr 03, 2026. The company reported -C$0.016 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.016.
Is Lexston Life Sciences Corp. overvalued?
According to Wall Street analysts Lexston Life Sciences Corp.’s price is currently Overvalued.
Does Lexston Life Sciences Corp. pay dividends?
Lexston Life Sciences Corp. does not currently pay dividends.
What is Lexston Life Sciences Corp.’s EPS estimate?
Lexston Life Sciences Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lexston Life Sciences Corp. have?
Lexston Life Sciences Corp. has 25,093,304 shares outstanding.
What happened to Lexston Life Sciences Corp.’s price movement after its last earnings report?
Lexston Life Sciences Corp. reported an EPS of -C$0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.263%.
Which hedge fund is a major shareholder of Lexston Life Sciences Corp.?
Currently, no hedge funds are holding shares in TSE:LEXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lexston Life Sciences Corp.
Lexston Life Sciences Corp. operates as a biotechnology company that provides cannabis testing and research services in Canada. The company also offers analytical testing for cannabis, pathogens, and toxins. In addition, it focuses on developing and validating methods for standardized manufacturing of plant derived psychedelics in the field of mental health and wellness. The company is based in Vancouver, Canada.
Technical Analysis
Options Prices
Currently, No data available
---